Tishcon (United States)

Curcumin (Cur), demethoxycurcumin (DMC), and bis‐demethoxycurcumin (BDMC) are the main curcuminoids in Curcuma longa used to prepare the spice turmeric. Cur has been shown to reduce the risk of cancer, inflammation and Alzheimers. As such, it has become increasingly popular in foods and dietary supplements. To examine content and bioaccessibility of commercial Cur products, we developed and validated an HPLC method to measure Cur and metabolites. Dietary supplements were processed via an in vitro digestion (simulated gastric and small intestinal phases) and Caco‐2 cellular uptake (Chitchumroonchokchai et al., J. Nutr. 2004). Cur, DMC, BDMC were monitored at 425nm for sensitive detection and 280nm was monitored to detect the internal standard, Flavone, and cellular metabolites of curcuminoids. Three products were tested containing from 10% to 95% curcuminoids. The micellarized Cur was stable in cell culture medium for at least 4 hrs. Transfer of Cur from the supplements to micelles during the small intestinal phase of digestion varied markedly between the two products. Micellarization was more efficient as polarity increased, i.e., BDMC> DMC>Cur. Efficiency (%) of incorporation into micelles was higher for Curcu‐Gel™ than Turm’Brite 10% sd Cur, 29.1% vs 8.7%. Cur in synthetic micelles was taken up by the cells in a time and concentration dependent manner. (Supported in part by Tishcon Corp., Westbury, NY)

Journal of Medicinal FoodVol. 9, No. 1 Letters to the EditorOn the Bioequivalence and Bioavailability of Three Coenzyme Q10 ProductsRaj K. Chopra and Hemmi N. BhagavanRaj K. ChopraSearch for more papers by this author and Hemmi N. BhagavanSearch for more papers by this authorPublished Online:31 Mar 2006https://doi.org/10.1089/jmf.2006.9.131AboutSectionsPDF/EPUB ToolsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail "On the Bioequivalence and Bioavailability of Three Coenzyme Q10 Products." , 9(1), pp. 131–132FiguresReferencesRelatedDetailsCited byCoenzyme Q10 and α-tocopherol reversed age-associated functional impairments in miceExperimental Gerontology, Vol. 58 Volume 9Issue 1Mar 2006 InformationCopyright 2006, Mary Ann Liebert, Inc.To cite this article:Raj K. Chopra and Hemmi N. Bhagavan.On the Bioequivalence and Bioavailability of Three Coenzyme Q10 Products.Journal of Medicinal Food.Mar 2006.131-132.http://doi.org/10.1089/jmf.2006.9.131Published in Volume: 9 Issue 1: March 31, 2006PDF download

ABSTRACTThe purpose of this investigation was to compare the bioavailability of three coenzyme Q10 (CoQ10) formulations in dogs using an open, randomized, multiple-dose crossover design. The formulations included a powder-filled capsule (A, control) and two soft gelatin formulations (Q-Gel ® as the water-miscible form of CoQ10, B and Q-Nol™as the water-miscible form of ubiquinol, the reduced form of CoQ10, C). Formulations were evaluated in pairs, allowing a washout period of 14 days prior to crossing over. Blood samples were collected from each animal prior to dosing to determine the endogenous plasma CoQ10 concentrations. Serial blood samples were collected for 72 hr and plasma CoQ10 concentrations were determined by high-performance liquid chromatography. Plasma concentration–time profiles were corrected for endogenous CoQ10 concentrations. Results showed that the relative bioavailabilities of formulations B and C were approximately 3.6 and 6.2-fold higher than that of control formulation A. The AUC(µg. hr/mL)±SD, Cmax(µg/mL)±SD, and Tmax(hr)± SD for formulations A, B, and C were 1.695±0.06, 6.097±0.08, and 10.510±0.10; 0.096±0.035, 0.169±0.038, and 0.402±0.102; and 4.2±1.48, 4.1±1.57, and 4.5±0.58, respectively. While no significant differences were observed between Tmax values of the three formulations, the AUC and Cmax values for formulations B and C were significantly higher than those of the control (p<0.05). The present investigation demonstrates that soft gelatin capsules containing water-miscible CoQ10 formulations B (Q-Gel®) and C (Q-Nol™) are superior to powder-filled formulations with regard to their biopharmaceutical characteristics.